Clinical and cost comparison of ibutilide and direct-current cardioversion for atrial fibrillation and flutter
2000; Elsevier BV; Volume: 85; Issue: 4 Linguagem: Inglês
10.1016/s0002-9149(99)00782-1
ISSN1879-1913
AutoresDavid K. Murdock, Glen T. Schumock, Jeffrey W. Kaliebe, Karen Olson, Amy J. Guenette,
Tópico(s)Cardiovascular Syncope and Autonomic Disorders
ResumoDirect-current cardioversion (DCC) is the most common method used to convert atrial fibrillation (AF) and atrial flutter (AFl) when the arrhythmia is >48 hours’ duration. 1 Kerber RE. Transthoracic cardioversion of atrial fibrillation and flutter: Standard techniques and new advances. Am J Cardiol 1996;78(suppl 8A):22–26. 12. Google Scholar , 2 Goldman M.J The management of chronic atrial fibrillation indications and method of cardioversion to sinus rhythm. Prog Cardiovasc Dis. 1959; 2: 465-479 Crossref Scopus (87) Google Scholar Ibutilide fumarate (ibutilide) has recently been approved by the Food & Drug Administration to convert AF and AFl of recent onset (0 to 90 days). 3 Corvert injection (ibutilide fumarate). Package insert, The Upjohn Company, Kalamazoo, MI: 1/96. Google Scholar The purpose of this study was to compare the clinical effectiveness and costs of a conversion strategy using first-line ibutilide versus DCC for recent-onset AF or AFl in patients undergoing anticoagulation for 3 to 4 weeks before elective cardioversion.
Referência(s)